GLPG (Galapagos Genomics) Gross Margin

Official company branding of Galapagos Genomics (GLPG)

Galapagos NV is aggressively acquiring startups, shifting its focus from immunology to the rapid production of cell therapies for oncology clinics. Absolute gross margin demonstrates cost efficiency, with the indicator standing at 97.40. Consequently, Galapagos NV aims for global leadership in CAR-T therapy by implementing accelerated treatment delivery to patients via an innovative platform.

Galapagos NV - GLPG Gross Margin (period 07/04/2022 - 05/08/2026)

Analytical breakdowns and data insights for company Galapagos N.V. (GLPG)

- share price and consensus valuation forecast:
- business market valuation indicators:
Basic company analysis:GLPG - Galapagos Genomics
Original product of Galapagos

Gross margin measures production efficiency by determining the profit share after deducting direct costs of product creation. By analyzing gross margin fluctuations, an investor assesses the operating profitability of Galapagos NV (GLPG), which depends directly on drug development costs and the commercial success of clinical trials conducted through partnerships with pharmaceutical behemoths.

Key competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|ANI Pharmaceuticals (ANIP) - Gross Profitability|Gross Return on Sales MNKD|Gross Profitability Amphastar Pharmaceuticals, Inc.|Pacira Pharmaceuticals (PCRX) - Return on Sales by Gross Profit|Gross Margin SPRY|TBPH - Gross Profit Margin|Aquestive Pharma - Return on Gross Profit|Gross Margin scpharmaceuticals.com SCPH|Tectonic - Gross Margin|TNXP - Gross Margin|SXTC: Gross Margin|Eupraxia Pharma - Gross Profit Rate|BHST (bioharvest.com) - Gross Margin|Gross Return on Sales EXOZ (invizyne.com)|Gross Margin ORMP|Return on Sales by Gross Profit Entera Bio|Gross Margin HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Gross Profitability|Cumberland Corp - Gross Margin|QNTM - Gross Margin|FibroGen, Inc. (FGEN) - Gross Profitability|TELO: Gross Profit Ratio|RANI (Rani Therapeutics Inc) - Gross Margin|Gross Profit Margin synergychc.com SNYR|Gross Profitability Rallybio Corp. (RLYB)|LEXX - Gross Profit Margin|Gross Margin PULM (pulmatrix.com)|Gross Profit Ratio PTHL (Pheton)|APM - Gross Profitability|Return on Sales by Gross Profit Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin